185 related articles for article (PubMed ID: 21864181)
1. Abiraterone and increased survival in metastatic prostate cancer.
Sonpavde G
N Engl J Med; 2011 Aug; 365(8):766-7; author reply 767-8. PubMed ID: 21864181
[No Abstract] [Full Text] [Related]
2. Abiraterone and increased survival in metastatic prostate cancer.
Berruti A; Pia A; Terzolo M
N Engl J Med; 2011 Aug; 365(8):766; author reply 767-8. PubMed ID: 21864182
[No Abstract] [Full Text] [Related]
3. Expanding treatment options for metastatic prostate cancer.
Antonarakis ES; Eisenberger MA
N Engl J Med; 2011 May; 364(21):2055-8. PubMed ID: 21612475
[No Abstract] [Full Text] [Related]
4. Abiraterone acetate (Zytiga) for metastatic castration-resistant prostate cancer.
Med Lett Drugs Ther; 2011 Aug; 53(1370):63-4. PubMed ID: 21836546
[No Abstract] [Full Text] [Related]
5. Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer.
Omlin A; Pezaro CJ; Zaidi S; Lorente D; Mukherji D; Bianchini D; Ferraldeschi R; Sandhu S; Dearnaley D; Parker C; Van As N; de Bono JS; Attard G
Br J Cancer; 2013 Sep; 109(5):1079-84. PubMed ID: 23928659
[TBL] [Abstract][Full Text] [Related]
6. Abiraterone and increased survival in metastatic prostate cancer.
de Bono JS; Logothetis CJ; Molina A; Fizazi K; North S; Chu L; Chi KN; Jones RJ; Goodman OB; Saad F; Staffurth JN; Mainwaring P; Harland S; Flaig TW; Hutson TE; Cheng T; Patterson H; Hainsworth JD; Ryan CJ; Sternberg CN; Ellard SL; Fléchon A; Saleh M; Scholz M; Efstathiou E; Zivi A; Bianchini D; Loriot Y; Chieffo N; Kheoh T; Haqq CM; Scher HI;
N Engl J Med; 2011 May; 364(21):1995-2005. PubMed ID: 21612468
[TBL] [Abstract][Full Text] [Related]
7. [Castration resistant prostate cancer 2011].
Miller K
Aktuelle Urol; 2011 Mar; 42(2):95-102. PubMed ID: 21437832
[TBL] [Abstract][Full Text] [Related]
8. Abiraterone acetate: a novel drug for castration-resistant prostate carcinoma.
Nandha R
J Postgrad Med; 2012; 58(3):203-6. PubMed ID: 23023354
[TBL] [Abstract][Full Text] [Related]
9. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?
Mezynski J; Pezaro C; Bianchini D; Zivi A; Sandhu S; Thompson E; Hunt J; Sheridan E; Baikady B; Sarvadikar A; Maier G; Reid AHM; Mulick Cassidy A; Olmos D; Attard G; de Bono J
Ann Oncol; 2012 Nov; 23(11):2943-2947. PubMed ID: 22771826
[TBL] [Abstract][Full Text] [Related]
10. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.
Reid AH; Attard G; Danila DC; Oommen NB; Olmos D; Fong PC; Molife LR; Hunt J; Messiou C; Parker C; Dearnaley D; Swennenhuis JF; Terstappen LW; Lee G; Kheoh T; Molina A; Ryan CJ; Small E; Scher HI; de Bono JS
J Clin Oncol; 2010 Mar; 28(9):1489-95. PubMed ID: 20159823
[TBL] [Abstract][Full Text] [Related]
11. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer.
Attard G; Belldegrun AS; de Bono JS
BJU Int; 2005 Dec; 96(9):1241-6. PubMed ID: 16287438
[No Abstract] [Full Text] [Related]
12. Combination therapy: Abiraterone prolongs survival in metastatic prostate cancer.
Sartor O
Nat Rev Clin Oncol; 2011 Aug; 8(9):515-6. PubMed ID: 21808270
[TBL] [Abstract][Full Text] [Related]
13. [Inhibitors of the key enzymes of androgen synthesis: potential agents as targets for prostate cancer].
Takeda M; Hosaka M
Nihon Rinsho; 2000 Jul; 58 Suppl():312-6. PubMed ID: 11022738
[No Abstract] [Full Text] [Related]
14. Agents that target androgen synthesis in castration-resistant prostate cancer.
Ferraldeschi R; de Bono J
Cancer J; 2013; 19(1):34-42. PubMed ID: 23337755
[TBL] [Abstract][Full Text] [Related]
15. Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer.
Salem M; Garcia JA
Curr Oncol Rep; 2011 Apr; 13(2):92-6. PubMed ID: 21243537
[TBL] [Abstract][Full Text] [Related]
16. [Promising on advanced cancer, several new drugs coming].
Widmark A; Karlsson CT
Lakartidningen; 2012 Feb 22-28; 109(8):416-9. PubMed ID: 22509668
[No Abstract] [Full Text] [Related]
17. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
Attard G; Reid AH; A'Hern R; Parker C; Oommen NB; Folkerd E; Messiou C; Molife LR; Maier G; Thompson E; Olmos D; Sinha R; Lee G; Dowsett M; Kaye SB; Dearnaley D; Kheoh T; Molina A; de Bono JS
J Clin Oncol; 2009 Aug; 27(23):3742-8. PubMed ID: 19470933
[TBL] [Abstract][Full Text] [Related]
18. Management of docetaxel failures in metastatic castrate-resistant prostate cancer.
Pal SK; Lewis B; Sartor O
Urol Clin North Am; 2012 Nov; 39(4):583-91. PubMed ID: 23084533
[TBL] [Abstract][Full Text] [Related]
19. The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature.
Sonpavde G; Attard G; Bellmunt J; Mason MD; Malavaud B; Tombal B; Sternberg CN
Eur Urol; 2011 Aug; 60(2):270-8. PubMed ID: 21550166
[TBL] [Abstract][Full Text] [Related]
20. Abiraterone in prostate cancer: a new angle to an old problem.
Stein MN; Goodin S; Dipaola RS
Clin Cancer Res; 2012 Apr; 18(7):1848-54. PubMed ID: 22451619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]